GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Issuance of Debt

ONCT (Oncternal Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Issuance of Debt?

Oncternal Therapeutics's Issuance of Debt for the three months ended in Sep. 2024 was $0.00 Mil.

Oncternal Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Oncternal Therapeutics Issuance of Debt Historical Data

The historical data trend for Oncternal Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Issuance of Debt Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.30 - - -

Oncternal Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncternal Therapeutics Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Issuance of Debt
Comparable Companies
TSOI WINT TRVN SCPX ADTX HEPA GBLX KRBP HALB PBLA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 ONC
Traded in Other Exchanges
N/A
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Website
https://www.oncternal.com
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Executives
Robert James Wills director, officer: Executive Chairman 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Gunnar F. Kaufmann officer: Chief Scientific Officer C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji officer: Chief Medical Officer 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer director, officer: President, CEO
Richard G Vincent officer: Chief Financial Officer C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan officer: Chief Technology Officer 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen director 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
Hazel M Aker officer: General Counsel C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Shanghai Pharmaceutical (usa) Inc. 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Shanghai Pharmaceuticals (hk) Investment Ltd 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130